Paul A. Clark

University of Wisconsin–Madison — United States

Medicine · Health Sciences

43h-index5.0kcitations197works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(37), Radiopharmaceutical Chemistry and Applications(22), Cancer Immunotherapy and Biomarkers(18), Histone Deacetylase Inhibitors Research(16), Cancer Cells and Metastasis(15)

Publications197 total

Mixed-Valent Tetracopper Disulfides Supported by a 1,8-Naphthyridine-Based Ligand: Models for Electronic Communication in Biological Copper Systems
Journal of the American Chemical Society·2026
Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice
Nature Communications·2026Open Access
Radionuclide-Dependent Stimulation of Antitumor Immunity in GD2-Targeted Radiopharmaceutical Therapy Combined with Immune Checkpoint Inhibitors
Radiation·2025Open Access
Abstract C090: Development of a multi-functional CAIX-TGFβ targeted radiopharmaceutical for triple-negative breast cancer
Molecular Cancer Therapeutics·2025
PT2.13.04 Real-World Multi-Institution Analysis of Patients With Small Cell Lung Cancer Treated With Tarlatamab
Journal of Thoracic Oncology·2025
Figure S9 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Supplementary Tables from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Figure S6 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Figure S2 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Figure S4 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Figure S8 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Figure S1 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Figure S5 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Figure S3 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Figure S7 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Data from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
2025Open Access
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study
Journal of Thoracic Oncology·2025· 4 citedOpen Access
SUZ12–Nucleic Acid Interactions Constrain PRC2 Activity to Maintain Targeted Gene Silencing Essential to Diffuse Midline Glioma
2025Open Access
Joint position on quality indicators for fragility hip fracture in Mexico
Archives of Osteoporosis·2025
The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy
Cancer Immunology Research·2025· 3 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

John S. Kuo(22), Jeremy J. Mao(6), S. Ted Oyama(5), Michael Zorniak(5), Kelli B. Pointer(5), Eduardo K. Moioli(4), M. Shahriar Salamat(4), Dandan Sun(4), Maxwell Drain(3), Daniel M. Treisman(3), Jamey P. Weichert(3), Wen Zhu(3), Johnathan Ebben(3), Kevin W. Eliceiri(2), Félix G. Requejo(2), Irawati Kandela(2), Mohammed Farhoud(2), Kyle I. Swanson(2), Gulnaz Begum(2), Kristopher T. Kahle(2)